Literature DB >> 28320634

Can allogeneic stem cells improve outcomes after stroke?

Steven C Cramer1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28320634      PMCID： PMC5739028          DOI： 10.1016/S1474-4422(17)30075-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  9 in total

1.  The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents.

Authors:  Steven C Cramer; Walter J Koroshetz; Seth P Finklestein
Journal:  Stroke       Date:  2007-03-01       Impact factor: 7.914

Review 2.  Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy.

Authors:  J Grotta
Journal:  J Intern Med       Date:  1995-01       Impact factor: 8.989

Review 3.  Considerations in the design of clinical trials of neuroprotective therapy in acute stroke.

Authors:  P J Dorman; P A Sandercock
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

4.  Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  David C Hess; Lawrence R Wechsler; Wayne M Clark; Sean I Savitz; Gary A Ford; David Chiu; Dileep R Yavagal; Ken Uchino; David S Liebeskind; Alexander P Auchus; Souvik Sen; Cathy A Sila; Jeffrey D Vest; Robert W Mays
Journal:  Lancet Neurol       Date:  2017-03-17       Impact factor: 44.182

5.  Stroke Recovery and Rehabilitation Research: Issues, Opportunities, and the National Institutes of Health StrokeNet.

Authors:  Steven C Cramer; Steven L Wolf; Harold P Adams; Daofen Chen; Alexander W Dromerick; Kari Dunning; Caitlyn Ellerbe; Andrew Grande; Scott Janis; Maarten G Lansberg; Ronald M Lazar; Yuko Y Palesch; Lorie Richards; Elliot Roth; Sean I Savitz; Lawrence R Wechsler; Max Wintermark; Joseph P Broderick
Journal:  Stroke       Date:  2017-02-07       Impact factor: 7.914

6.  Selective neuronal loss in rescued penumbra relates to initial hypoperfusion.

Authors:  J V Guadagno; P S Jones; F I Aigbirhio; D Wang; T D Fryer; D J Day; N Antoun; I Nimmo-Smith; E A Warburton; J C Baron
Journal:  Brain       Date:  2008-08-04       Impact factor: 13.501

Review 7.  Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  Carolee J Winstein; Joel Stein; Ross Arena; Barbara Bates; Leora R Cherney; Steven C Cramer; Frank Deruyter; Janice J Eng; Beth Fisher; Richard L Harvey; Catherine E Lang; Marilyn MacKay-Lyons; Kenneth J Ottenbacher; Sue Pugh; Mathew J Reeves; Lorie G Richards; William Stiers; Richard D Zorowitz
Journal:  Stroke       Date:  2016-05-04       Impact factor: 7.914

8.  Harnessing neuroplasticity for clinical applications.

Authors:  Steven C Cramer; Mriganka Sur; Bruce H Dobkin; Charles O'Brien; Terence D Sanger; John Q Trojanowski; Judith M Rumsey; Ramona Hicks; Judy Cameron; Daofen Chen; Wen G Chen; Leonardo G Cohen; Christopher deCharms; Charles J Duffy; Guinevere F Eden; Eberhard E Fetz; Rosemarie Filart; Michelle Freund; Steven J Grant; Suzanne Haber; Peter W Kalivas; Bryan Kolb; Arthur F Kramer; Minda Lynch; Helen S Mayberg; Patrick S McQuillen; Ralph Nitkin; Alvaro Pascual-Leone; Patricia Reuter-Lorenz; Nicholas Schiff; Anu Sharma; Lana Shekim; Michael Stryker; Edith V Sullivan; Sophia Vinogradov
Journal:  Brain       Date:  2011-04-10       Impact factor: 13.501

9.  Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease.

Authors:  Yi Lin; William J Hogan
Journal:  Adv Hematol       Date:  2011-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.